MorphoSys AG has revised upward its profit forecast for 2013 in light of stronger than anticipated revenue, and lower than expected costs for the development of a therapeutic antibody for cancer which is partnered with Celgene Inc. ---Subscribe to MedNous to access this article--- Company News
